Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc.已成为2023年12月31日向美国证券交易委员会（SEC）提交的附表13G/A修正案的主题。文件显示，Great Point Partners, LLC以及医学博士杰弗里·杰伊博士和Ortav Yehudai先生报告了对Avalo Therapeutics普通股的2,085股的共享投票权和处置权，普通股占该公司证券类别的0.26％。有关股票与受实益所有权上限约束的认股权证有关，如果认股权证的所有权超过已发行普通股的9.99％，则无法行使认股权证。该文件日期为2024年2月14日，还包括申报人之间的联合申报协议，表明他们打算根据美国证券交易委员会的规定共同提交本声明。申报人已放弃对股票的实益所有权，但金钱利益除外，该文件证明收购这些股份不是为了改变或影响Avalo Therapeutics的控制权。
Avalo Therapeutics, Inc.已成为2023年12月31日向美国证券交易委员会（SEC）提交的附表13G/A修正案的主题。文件显示，Great Point Partners, LLC以及医学博士杰弗里·杰伊博士和Ortav Yehudai先生报告了对Avalo Therapeutics普通股的2,085股的共享投票权和处置权，普通股占该公司证券类别的0.26％。有关股票与受实益所有权上限约束的认股权证有关，如果认股权证的所有权超过已发行普通股的9.99％，则无法行使认股权证。该文件日期为2024年2月14日，还包括申报人之间的联合申报协议，表明他们打算根据美国证券交易委员会的规定共同提交本声明。申报人已放弃对股票的实益所有权，但金钱利益除外，该文件证明收购这些股份不是为了改变或影响Avalo Therapeutics的控制权。
有用
没用